Sarepta Therapeutics Inc. (SRPT) released positive preliminary results from its Phase 1/2a gene therapy clinical trial of micro-Dystrophin on Tuesday in three children with Duchenne muscular dystrophy.
from RTT - Before the Bell https://ift.tt/2M4ODDm
via IFTTT
No comments:
Post a Comment